完全性葡萄胎与共存正常胎儿的多胎妊娠:非随机研究的临床结局系统综述与Meta分析
该系统综述与Meta分析纳入19项研究共417例组织学确诊的完全性葡萄胎与共存正常胎儿(CHMCF)病例,汇总各项临床结局的发生比例。结果显示流产、子痫前期、小于胎龄儿、产后出血和早产风险较高,早期终止妊娠并未明确降低妊娠滋养细胞肿瘤风险,证据等级为低至极低。
要点
- CHMCF中超声诊断占76.0%,52.7%于早孕期诊断,80.5%诊断时有症状,阴道出血最常见。
- 活产比例46.5%,其中71.2%经剖宫产分娩;早产(<37周)占67.8%,流产占32.7%。
- 妊娠滋养细胞肿瘤总比例为33.8%,早期终止妊娠并未明确降低其风险。
核心结论
- CHMCF妊娠面临较高的母体、产科和新生儿并发症风险,包括流产、子痫前期、小于胎龄儿、产后出血和早产。
- 早期终止妊娠并未明确降低妊娠滋养细胞肿瘤的发生风险。
- 推荐早期诊断、转诊至具有滋养细胞疾病专业知识的母胎医学单元,并广泛实施早产和子痫前期筛查方案以促进及时干预改善结局。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和Scopus数据库自建库至2024年10月1日。
- 纳入至少3例组织学确诊CHMCF的病例系列和队列研究,定量合成纳入19项研究共417例。
- 采用随机效应模型合并比例,Higgins I²指数评估异质性,Newcastle-Ottawa量表和Joanna Briggs研究所批判性评价清单评估研究质量,GRADE方法评估证据确定性。
- 研究注册于PROSPERO数据库(CRD42023431734)。
主要发现
- 超声诊断占76.0%(95%CI 58.5-90.6%),早孕期诊断占52.7%(95%CI 34.0-71.0%),诊断时有症状占80.5%(95%CI 66.1-92.3%),阴道出血为诊断时及孕期 later 最常见症状。
- 选择性终止妊娠合并比例为48.8%(95%CI 32.7-65.1%),其中因母体并发症终止占6.2%(95%CI 1.0-13.9%);活产合并比例为46.5%(95%CI 36.1-57.1%),其中71.2%(95%CI 42.4-94.4%)经剖宫产分娩。
- 早产(<37周)占67.8%(95%CI 44.7-88.1%),极早产(<32周)占12.4%(95%CI 0.2-33.9%),流产(胎儿死亡<24周)占32.7%(95%CI 26.1-39.6%)。
- 子痫前期占17.8%(95%CI 5.9-32.7%),产后出血占42.7%(95%CI 5.1-84.8%),小于胎龄儿(出生体重<第10百分位)占40.6%(95%CI 12.9-70.8%),新生儿和母体死亡率可忽略不计。
- 妊娠滋养细胞肿瘤合并比例为33.8%(95%CI 25.6-42.5%);选择性终止妊娠、继续妊娠和活产中分别为14.1%(95%CI 5.4-24.9%)、20.3%(95%CI 12.0-29.9%)和5.9%(95%CI 1.9-11.2%)。
关键数值与推荐
- GRADE证据等级为低至极低。
- 推荐早期诊断、转诊至具有滋养细胞疾病专业知识的母胎医学单元,并广泛实施早产和子痫前期筛查方案。
临床怎么用
- CHMCF妊娠应早期诊断并转诊至具有滋养细胞疾病专业知识的母胎医学单元。
- 广泛实施早产和子痫前期筛查方案,以促进及时干预改善结局。
局限性
- GRADE证据等级为低至极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Complete hydatidiform mole and coexisting normal fetus (CHMCF) is a rare condition for which there is significant heterogeneity in diagnosis, counseling and management of complications. The objective of this study was to summarize the prevalence of clinical outcomes in reported cases of CHMCF. METHODS: A systematic literature search was conducted in PubMed, Embase and Scopus databases from inception until 1 October 2024. Case series and cohort studies including at least three cases of histologically confirmed CHMCF were included. A random-effects model was used for meta-analysis of proportions and heterogeneity was estimated using Higgins' I2 index. The Newcastle-Ottawa scale and the Joanna Briggs Institute critical appraisal checklist were used to assess study quality, while certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. The study was registered in the PROSPERO database (CRD42023431734). RESULTS: Quantitative synthesis included 19 studies and 417 cases of CHMCF. Diagnosis was made using ultrasound in 76.0% (95% CI, 58.5-90.6%) of cases and occurred in the first trimester in 52.7% (95% CI, 34.0-71.0%). Symptoms at diagnosis were present in 80.5% (95% CI, 66.1-92.3%) of cases, with vaginal bleeding being the most common symptom both at diagnosis and later in pregnancy. The pooled proportion of elective pregnancy termination was 48.8% (95% CI, 32.7-65.1%), with 6.2% (95% CI, 1.0-13.9%) due to maternal complications. The pooled proportion of live births was 46.5% (95% CI, 36.1-57.1%), with most being delivered by Cesarean section (71.2% (95% CI, 42.4-94.4%)). Preterm birth (< 37 weeks) occurred in 67.8% (95% CI, 44.7-88.1%) of cases, very preterm birth (< 32 weeks) in 12.4% (95% CI, 0.2-33.9%) and miscarriage (fetal death < 24 weeks) in 32.7% (95% CI, 26.1-39.6%). Pre-eclampsia was present in 17.8% (95% CI, 5.9-32.7%) of cases and postpartum hemorrhage occurred in 42.7% (95% CI, 5.1-84.8%). A small-for-gestational-age neonate (birth weight < 10th percentile) was delivered in 40.6% (95% CI, 12.9-70.8%) of cases. Rates of neonatal and maternal mortality were negligible. The pooled proportion of gestational trophoblastic neoplasia was 33.8% (95% CI, 25.6-42.5%); among elective terminations, continued pregnancies and live births, the rates were 14.1% (95% CI, 5.4-24.9%), 20.3% (95% CI, 12.0-29.9%) and 5.9% (95% CI, 1.9-11.2%), respectively. The evidence level according to GRADE was low to very low. CONCLUSIONS: Pregnancies with CHMCF present a high risk of maternal, obstetric and neonatal complications, including miscarriage, pre-eclampsia, small-for-gestational age, postpartum hemorrhage and preterm birth. The risk of developing gestational trophoblastic neoplasia was not clearly mitigated by early pregnancy termination. Early diagnosis, referral to a maternal-fetal medicine unit with expertise in trophoblastic disorders and extensive implementation of screening protocols for preterm birth and pre-eclampsia are recommended to facilitate timely intervention aimed at outcome improvement. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Salmeri N, Pizzetti A, Grassi E, et al. Multiple pregnancy with complete hydatidiform mole and coexisting normal fetus: systematic review and meta-analysis of clinical outcomes from non-randomized studies. Ultrasound Obstet Gynecol. 2025. PMID: 41066778. doi:10.1002/uog.70104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。